HighTower Advisors
DRNA

HighTower Advisors’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

HighTower Advisors’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-14,509
Closed -$222K – 2417
2018
Q3 		$222K Buy
+14,509
New +$211K ﹤0.01% 1895

Other funds holding DRNA

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HighTower Advisors's DRNA Position: Q4 2018 in Review

HighTower Advisors sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2018, closing a stake of 14,509 shares — an estimated $222K sold.

HighTower Advisors first reported a position in DRNA in Q3 2018 and held it in 1 quarter. The position peaked at $222K in Q3 2018. 103 funds tracked by Wall St. Rank hold DRNA as of Q4 2018.

  • HighTower Advisors reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
  • HighTower Advisors sold 14,509 Dicerna Pharmaceuticals, Inc. shares in Q4 2018, an estimated $222K.
  • HighTower Advisors first reported a position in Dicerna Pharmaceuticals, Inc. in Q3 2018 and held it in 1 quarter.
  • HighTower Advisors's Dicerna Pharmaceuticals, Inc. position peaked at $222K in Q3 2018.
  • 103 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2018.

Based on HighTower Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.